Sensus Healthcare (NASDAQ:SRTS – Get Free Report) is expected to post its Q3 2026 results after the market closes on Thursday, November 12th. Analysts expect the company to announce earnings of ($0.0550) per share and revenue of $6.61 million for the quarter. Individuals may visit the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Thursday, November 12, 2026 at 4:30 PM ET.
Sensus Healthcare (NASDAQ:SRTS – Get Free Report) last announced its earnings results on Thursday, August 13th. The company reported ($0.53) EPS for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.41). The business had revenue of $2.29 million during the quarter, compared to analyst estimates of $4.60 million. Sensus Healthcare had a negative net margin of 88.45% and a negative return on equity of 21.57%.
Sensus Healthcare Stock Performance
Shares of SRTS opened at $3.25 on Thursday. The company has a 50-day moving average of $3.02 and a two-hundred day moving average of $3.52. Sensus Healthcare has a 12-month low of $2.66 and a 12-month high of $5.49.
Analyst Ratings Changes
Get Our Latest Stock Report on SRTS
Insider Activity at Sensus Healthcare
In other news, Director Eric Sachetta acquired 37,537 shares of Sensus Healthcare stock in a transaction dated Friday, August 28th. The stock was acquired at an average cost of $3.44 per share, for a total transaction of $129,127.28. Following the completion of the purchase, the director owned 267,480 shares of the company’s stock, valued at $920,131.20. This represents a 16.32% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this link. Insiders have purchased a total of 120,171 shares of company stock valued at $405,230 over the last 90 days. Company insiders own 10.20% of the company’s stock.
Sensus Healthcare Company Profile
Sensus Healthcare, Inc is a medical device company focused on non-invasive treatment technologies for dermatologic and oncologic conditions. The company develops and commercializes superficial radiotherapy systems designed to deliver low-energy X-rays to targeted areas of the skin.
Its principal products include the SRT-100 and SRT-100 Vision systems, which are used by physicians to treat non-melanoma skin cancers, including basal cell and squamous cell carcinomas, as well as keloids. The systems are intended to provide an alternative to certain surgical procedures and are used in dermatology, radiation oncology and other clinical settings.
Founded in 2010, Sensus Healthcare is headquartered in Boca Raton, Florida.
See Also
- Five stocks we like better than Sensus Healthcare
- Why ExxonMobil and Chevron Reminded Investors to Keep it Simple
- Amazon Has Erased Its Earnings Sell-Off, But Is the Biggest Opportunity Still Ahead?
- onsemi’s AI Sales Surge 175%: Is a Stock Recovery Next?
- Energy Transfer’s Earnings Miss May Be Hiding Its Strongest Advantage
Receive News & Ratings for Sensus Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sensus Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.
